Urinary Markers Show Promise in ASD
Findings add to growing evidence in favor of microbiome-associated metabolite analysis for ASD screening and stratification
Clinical Scorecard: Urinary Markers Show Promise in ASD
At a Glance
| Category | Detail |
|---|
| Condition | Autism Spectrum Disorder (ASD) |
| Key Mechanisms | Microbially derived metabolites in urine |
| Target Population | Children aged 2 to 11 years with ASD |
| Care Setting | Laboratory-based screening |
Key Highlights
- Findings suggest potential for objective biomarkers in neurodevelopmental disorders.
Guideline-Based Recommendations
Diagnosis
- Use a panel of urinary microbially derived metabolites for identifying ASD subgroups.
Management
- Further validation of metabolite profiles is needed before clinical application.
Monitoring & Follow-up
- Monitor metabolite levels to assess potential ASD characteristics.
Risks
- Study limitations include small sample size and exclusion of children with known genetic causes.
Patient & Prescribing Data
Children with ASD and neurotypical controls aged 2 to 11 years.
Metabolite elevations vary significantly among individuals.
Clinical Best Practices
- Utilize established LC-MS methods for metabolite analysis.
- Consider multi-analyte signatures rather than single biomarkers for diagnosis.
Related Resources & Content
